Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinib
Latest Information Update: 20 Jan 2020
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALCSG-04
- 02 Aug 2017 New trial record